Accession Number PB2013-500001
Title A5221: Timing of Antiretroiral Theapy for HIV-1 Infection and Tuberculosis.
Publication Date 2012
Media Count 1one CD-ROM
Personal Author N/A
Abstract A5221/STRIDE was strategy trial to evaluate the timing of antiretroviral therapy (ART) during tuberculosis therapy. It included both patients with confirmed tuberculosis and those with suspected tuberculosis, since in clinical practice, the decision to start or delay ART must often be made before there is a definitive diagnosis of tuberculosis (a reflection of the current limitations of and access to tuberculosis diagnostics). Patients from a wide geographic spectrum were included to maximize the generalizability of the findings and to inform policy.
Keywords ACTG(AIDS Clinical Trials Group)
AIDS
Antiretroviral therapy
Clinical groups
Controlled trian
Datafile
HIV(Human immunodeficiency viruses)
Infection
Patients
SAS(Statistical Analysis System)
STRIDE
Treatment
Tuberculosis
 
Source Agency National Institute of Allergy and Infectious Disease
NTIS Subject Category 57E - Clinical Medicine
57J - Immunology
Corporate Author Harvard School of Public Health, Boston, MA. Dept. of Biostatistics.
Document Type Computer data file
Title Note N/A
NTIS Issue Number 1302
Contract Number N/A

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader